Evidence map›Paper›PMID 34384247›Full record

ArticleCirculation research2021

Yong Wang, Xiaoguang Lu, Xiaoping Wang, Qi Qiu, Ping Zhu, Lin Ma, Xiao Ma, Joerg Herrmann, Xueying Lin, Wei Wang and 1 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Circulation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06005259 (Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity), which is not on this map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06005259 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)

TypeinterventionalSponsorUniversity of Sao PauloRan2023 to 2025Enrolled264ConditionsCardiotoxicity, Neoplasms, Chemotherapy Effect, Heart FailureArmsSpironolactone, Placebo
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Yong Wang *Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.ORCID 0000-0003-3652-8037
Xiaoguang Lu *Biochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
Xiaoping Wang *School of Traditional Chinese Medicine (Y.W., X.W., L.M., W.W.), Beijing University of Chinese Medicine, China.ORCID 0000-0002-1370-490X
Qi QiuBiochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
Ping ZhuBiochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
Lin MaSchool of Traditional Chinese Medicine (Y.W., X.W., L.M., W.W.), Beijing University of Chinese Medicine, China.
Xiao MaBiochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.ORCID 0000-0001-9940-8468
Joerg HerrmannCardiovascular Medicine (Y.W., X. Lu, Q.Q., P.Z., X.M., J.H., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
Xueying LinBiochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.
Wei WangSchool of Traditional Chinese Medicine (Y.W., X.W., L.M., W.W.), Beijing University of Chinese Medicine, China.
Xiaolei XuBiochemistry and Molecular Biology (Y.W., X. Lu, Q.Q., P.Z., X.M., X. Lin, X.X.), Mayo Clinic, Rochester, MN.ORCID 0000-0002-4928-3422
X-Fab (Germany) · DEBeijing University of Chinese Medicine · CN

Funding

Genetic Studies of Sarcomere-based Cardiac Diseases (Diversity Supplement)R01HL081753 · NHLBI · MAYO CLINIC ROCHESTER · PI XU, XIAOLEI · 2005 to 2025
$7.8M
Epicardial remodeling in cardiomyopathy and cardiac agingR01HL107304 · NHLBI · MAYO CLINIC ROCHESTER · PI Xiaolei Xu · 2011 to 2026
$6.6M
NHLBI NIH HHS R01 HL081753NHLBI NIH HHS R01 HL107304
6 · The paper itself

Abstract

[Figure: see text].

Indexed as

AnimalsAntineoplastic AgentsAutophagyAutophagy-Related Protein 7CardiotoxicityDoxorubicinMyocarditisPravastatinSpironolactoneZebrafishZebrafish ProteinsAntineoplastic AgentsAutophagy-Related Protein 7DoxorubicinPravastatinSpironolactoneZebrafish Proteinsanthracyclineautophagycardiotoxicitydoxorubicinzebrafish

Identifiers

PMID34384247
PMCPMC8484060
OpenAlexW3189195948

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.